GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Tangible Book per Share

Evolutionary Genomics (Evolutionary Genomics) Tangible Book per Share : $-1.36 (As of Dec. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Evolutionary Genomics's tangible book value per share for the quarter that ended in Dec. 2022 was $-1.36.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Evolutionary Genomics Tangible Book per Share Historical Data

The historical data trend for Evolutionary Genomics's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolutionary Genomics Tangible Book per Share Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.73 -0.91 -1.14 -1.46 -1.36

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.46 -1.26 -1.29 -1.34 -1.36

Competitive Comparison of Evolutionary Genomics's Tangible Book per Share

For the Biotechnology subindustry, Evolutionary Genomics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evolutionary Genomics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Price-to-Tangible-Book falls into.



Evolutionary Genomics Tangible Book per Share Calculation

Evolutionary Genomics's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-5.592-1.835-1.651)/6.65523
=-1.36

Evolutionary Genomics's Tangible Book Value Per Share for the quarter that ended in Dec. 2022 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(-5.592-1.835-1.651)/6.65523
=-1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Evolutionary Genomics  (OTCPK:FNAM) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Evolutionary Genomics Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Evolutionary Genomics (Evolutionary Genomics) Business Description

Traded in Other Exchanges
N/A
Address
4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
Executives
Steve B Warnecke director, 10 percent owner, officer: Chairman, CEO C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff director 4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier officer: Secretary / Treasurer 1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess director 7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz director, 10 percent owner 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess director, 10 percent owner, officer: President/CEO 5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita director, officer: Secretary/Treasurer/CFO 5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines